What is 11Beta-HSD1?

11Beta-HSD1 inhibitors appear to be attractive R&D products for the treatment of type 2 diabetes, because a large number of major biotechnology and pharmaceutical companies are involved in their development, and this pipeline, although very young, already has 70% of products in clinical stage of development., according to a new report, titled Diabetes R&D Pipeline: 11beta-HSD1 inhibitors, added to the offering of Research and Markets.
11Beta-HSD1 (11beta-hydroxysteroid dehydrogenase type 1) antagonists are insulin sensitizers. 11beta-HSD1 is an enzyme that converts inactive cortisone into potent, biologically active hormone, cortisol. This conversion occurs within cells of key metabolic tissues including liver, adipose tissue, muscle tissue, and pancreas. Cortisol elevates blood glucose levels by increasing glucose production in liver, and by inhibiting uptake and disposal of glucose in muscle and adipose tissues.
More about: 11Beta-HSD1 sale
Read more: Proteases Enzyme